<![CDATA[Hansa Biopharma Year-end report January-December 2023]]>Hansa Biopharma Year-end report January-December 2023:

· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain

· Encouraging results from first-in-human trial of HNSA-5487

· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMD

Link Preview Image
Hansa Biopharma Year-end report January-December 2023 | Hansa Biopharma

favicon

(www.hansabiopharma.com)

]]>https://dev.proinvestor.com/forum/topic/446121/hansa-biopharma-year-end-report-january-december-2023RSS for NodeSat, 20 Jun 2026 13:51:01 GMTFri, 02 Feb 2024 06:27:23 GMT60<![CDATA[Reply to Hansa Biopharma Year-end report January-December 2023 on Fri, 02 Feb 2024 06:29:53 GMT]]>Hansa Biopharma will host a telephone conference Friday February 2, 2024, 14:00 CET / 8:00am EST.

The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, CCO, U.S. President, Matthew Shaulis, CSO Hitto Kaufmann and CFO, Donato Spota. The presentation will be held in English.

The webcast will be available on https://hansabiopharma.eventcdn.net/events/fullyear2023

]]>https://dev.proinvestor.com/forum/post/9486904https://dev.proinvestor.com/forum/post/9486904Fri, 02 Feb 2024 06:29:53 GMT